Selected article for: "case report and severe condition"

Author: Senegaglia, Alexandra Cristina; Rebelatto, Carmen Lúcia Kuniyoshi; Franck, Claudio Luciano; Lima, Juliana Souza; Boldrini-Leite, Lidiane Maria; Daga, Debora Regina; Leitão, Cleverson Alex; Shigunov, Patrícia; de Azambuja, Ana Paula; Bana, Elisa; Marsaro, Daniela Boscaro; Schaidt, Bruna; Micosky, Andressa; Jamur, Valderez Ravaglio; Schluga, Yara; Vaz, Isadora May; Ribeiro, Lisandro Lima; Correa, Alejandro; Brofman, e Paulo Roberto Slud
Title: Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report
  • Cord-id: u1i7ye1h
  • Document date: 2021_6_1
  • ID: u1i7ye1h
    Snippet: The coronavirus pandemic is one of the most significant public health events in recent history. Currently, no specific treatment is available. Some drugs and cell-based therapy have been tested as alternatives to decrease the disease’s symptoms, length of hospital stay, and mortality. We reported the case of a patient with a severe manifestation of COVID-19 in critical condition who did not respond to the standard procedures used, including six liters of O(2) supplementation under a nasal cath
    Document: The coronavirus pandemic is one of the most significant public health events in recent history. Currently, no specific treatment is available. Some drugs and cell-based therapy have been tested as alternatives to decrease the disease’s symptoms, length of hospital stay, and mortality. We reported the case of a patient with a severe manifestation of COVID-19 in critical condition who did not respond to the standard procedures used, including six liters of O(2) supplementation under a nasal catheter and treatment with dexamethasone and enoxaparin in prophylactic dose. The patient was treated with tocilizumab and an advanced therapy product based on umbilical cord-derived mesenchymal stromal cells (UC-MSC). The combination of tocilizumab and UC-MSC proved to be safe, with no adverse effects, and the results of this case report prove to be a promising alternative in the treatment of patients with severe acute respiratory syndrome due to SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents